Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00660101
Recruitment Status : Unknown
Verified December 2015 by AVAX Technologies.
Recruitment status was:  Active, not recruiting
First Posted : April 17, 2008
Last Update Posted : December 3, 2015
Information provided by (Responsible Party):
AVAX Technologies

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2015
  Estimated Study Completion Date : January 2016
Dunton CJ, Carlson JA, King SA, Bloome E, Neufeld J, Berd D. Immunological and clinical effects of autologous hapten-modified vaccine in patients with advanced ovarian carcinoma., 19: Abstract 1828 ed 2000. p. 466a.